Meeting the Latest Requirements for Residual Solvent Testing

The manufacturing process for active pharmaceutical ingredients (APIs) may contribute to residual solvents remaining in the final product. These organic solvents are widely used in the synthesis of pharmaceutical products and cannot always be completely removed during the manufacturing processes. Pharmaceutical manufacturers are required to monitor and control the levels of residual solvents to ensure no harmful compounds exceed permitted daily exposure for users and that the solvents have no impact on the safety, stability or efficacy of the formulation.

United States Pharmacopeia (USP) Method is used worldwide for quality control, and closely follows ICH Q3C guidelines. Upcoming updates to the ICH Q3C guideline expand the testing required for formulations.

This webinar will discuss the updates to the ICH Q3C requirements and show how Agilent's Residual Solvents Analyser; built to meet the USP 467 requirement is the ideal solution to your testing needs with the Smart, Connected and Self Aware capabilities of Agilent's latest systems ensuring your testing is right first time and every time.

Presenter: Bryan White (GC/MS Product Specialist, Agilent Technologies)

Bryan White is a product specialist for GC/MS at Agilent Technologies.

With over quarter of a century's experience in both chemical industry and Instrument manufacturing, Bryan has been with Agilent for the last 4 years. With 30 years of experience building and delivering analytical solutions and automated analysers to laboratories in many regulated industries have given Bryan a unique view of problem solving the most complex analytical issues with simple, easy to implement answers.